{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T05:21:17Z","timestamp":1734585677484,"version":"3.30.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Guidance Program of the Science and Technology Commission of Shanghai Municipality","award":["22JC1402303"],"award-info":[{"award-number":["22JC1402303"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-024-02571-x","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:20:11Z","timestamp":1734513611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of ground-glass component on prognosis in early-stage lung cancer treated with stereotactic body radiotherapy via Helical Tomotherapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Jintao","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaonan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"2571_CR1","doi-asserted-by":"crossref","unstructured":"Duma N, Santana-Davila R, Molina JR. (2019) Non\u2013Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings 94(8), 1623\u20131640.","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"2571_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.10.002","author":"CI Henschke","year":"2023","unstructured":"Henschke CI, Yip R, Sun Q, et al. Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a\u2013b; \u226420\u00a0mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery. J Thorac Oncol. 2023. https:\/\/doi.org\/10.1016\/j.jtho.2023.10.002.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2571_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2016.08.015","volume":"121","author":"J Nyman","year":"2016","unstructured":"Nyman J, Hallqvist A, Lund J-\u00c5, et al. SPACE \u2013 A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016;121(1):1\u20138.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2571_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","volume":"20","author":"D Ball","year":"2019","unstructured":"Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494\u2013503.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2571_CR5","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","volume":"22","author":"JY Chang","year":"2021","unstructured":"Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22(10):1448\u201357.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2571_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines\u00ae Insights: Non\u2013Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 2023;21(4):340\u201350.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2571_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","volume":"7","author":"GMM Videtic","year":"2017","unstructured":"Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Practical Radiation Oncol. 2017;7(5):295\u2013301.","journal-title":"Practical Radiation Oncol"},{"issue":"8","key":"2571_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","volume":"13","author":"S Senthi","year":"2012","unstructured":"Senthi S, Lagerwaard FJ, Haasbeek CJA, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13(8):802\u20139.","journal-title":"Lancet Oncol"},{"key":"2571_CR9","doi-asserted-by":"crossref","unstructured":"Tonneau M, Richard C, Routy B et al. (2023) A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Radiother Oncol 185.","DOI":"10.1016\/j.radonc.2023.109697"},{"issue":"1","key":"2571_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijrobp.2021.04.014","volume":"111","author":"Y Tateishi","year":"2021","unstructured":"Tateishi Y, Takeda A, Horita N, et al. Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Cancer. Int J Radiation Oncology*Biology*Physics. 2021;111(1):143\u201351.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"10","key":"2571_CR11","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1080\/0284186X.2019.1631476","volume":"58","author":"O Hansen","year":"2019","unstructured":"Hansen O, Kristiansen C, Nielsen M, Schytte T, Starup Jeppesen S. Survival after stereotactic radiotherapy in patients with early-stage non-small cell lung cancer. Acta Oncol. 2019;58(10):1399\u2013403.","journal-title":"Acta Oncol"},{"issue":"11","key":"2571_CR12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/jjco\/hyaa167","volume":"50","author":"A Kagimoto","year":"2020","unstructured":"Kagimoto A, Tsutani Y, Handa Y, Mimae T, Miyata Y, Okada M. Clinical features and prognosis of clinical N0 non-small cell lung cancer exceeding 30\u00a0mm. Jpn J Clin Oncol. 2020;50(11):1306\u201312.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2571_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.athoracsur.2017.01.076","volume":"104","author":"A Hattori","year":"2017","unstructured":"Hattori A, Matsunaga T, Takamochi K, Oh S, Suzuki K. Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer. Ann Thorac Surg. 2017;104(1):313\u201320.","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"2571_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jtho.2017.11.129","volume":"13","author":"K Aokage","year":"2018","unstructured":"Aokage K, Miyoshi T, Ishii G, et al. Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non\u2013Small Cell Lung Cancer. J Thorac Oncol. 2018;13(4):533\u201342.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2571_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/JTO.0b013e31821038ab","volume":"6","author":"KKT Suzuki","year":"2011","unstructured":"Suzuki KKT, Asakawa T, Kusumoto M, Asamura H, Nagai K, Tada H, Mitsudomi T, Tsuboi M, Shibata T, Fukuda H, Kato H, Japan Lung Cancer Surgical Study Group (Jcog Lcssg). A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011;6(4):751\u20136. A Prospective Radiological Study of Thin-Section Computed Tomography to Predic.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2571_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.athoracsur.2014.10.079","volume":"99","author":"S Xu","year":"2015","unstructured":"Xu S, Xi J, Jiang W, Lu S, Wang Q. Solid Component and Tumor Size Correlate With Prognosis of Stage IB Lung Adenocarcinoma. Ann Thorac Surg. 2015;99(3):961\u20137.","journal-title":"Ann Thorac Surg"},{"issue":"30","key":"2571_CR17","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","volume":"24","author":"R Timmerman","year":"2006","unstructured":"Timmerman R, Mcgarry R, Yiannoutsos C, et al. Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer. J Clin Oncol. 2006;24(30):4833\u20139.","journal-title":"J Clin Oncol"},{"key":"2571_CR18","doi-asserted-by":"crossref","unstructured":"Xi J, Yin J, Liang J et al. (2021) Prognostic Impact of Radiological Consolidation Tumor Ratio in Clinical Stage IA Pulmonary Ground Glass Opacities. Front Oncol 11.","DOI":"10.3389\/fonc.2021.616149"},{"issue":"7","key":"2571_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/JTO.0000000000000559","volume":"10","author":"R Rami-Porta","year":"2015","unstructured":"Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10(7):990\u20131003.","journal-title":"J Thorac Oncol"},{"issue":"10405","key":"2571_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023;402(10405):871\u201381.","journal-title":"Lancet"},{"issue":"4","key":"2571_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.4143\/crt.2022.1656","volume":"55","author":"JY Jang","year":"2023","unstructured":"Jang JY, Kim SS, Song SY, et al. Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience. Cancer Res Treat. 2023;55(4):1181\u20139.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"2571_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cllc.2022.03.007","volume":"23","author":"N Mikami","year":"2022","unstructured":"Mikami N, Takeda A, Hashimoto A, et al. CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy. Clin Lung Cancer. 2022;23(5):428\u201337.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"2571_CR23","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/JTO.0000000000000484","volume":"10","author":"HS Park","year":"2015","unstructured":"Park HS, Harder EM, Mancini BR, Decker RH. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non\u2013Small-Cell Lung Cancer. J Thorac Oncol. 2015;10(5):832\u20137.","journal-title":"J Thorac Oncol"},{"key":"2571_CR24","doi-asserted-by":"crossref","unstructured":"Timmerman RD, Paulus R, Pass HI et al. (2018) Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer. JAMA Oncol 4(9).","DOI":"10.1001\/jamaoncol.2018.1251"},{"issue":"7","key":"2571_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/1759-7714.14786","volume":"14","author":"YH Wu","year":"2023","unstructured":"Wu YH, Kang YM, Hu YW, et al. Old age and EGFR mutation status in inoperable early-stage non\u2010small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan. Thorac Cancer. 2023;14(7):654\u201361.","journal-title":"Thorac Cancer"},{"issue":"1","key":"2571_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijrobp.2011.06.2003","volume":"83","author":"FJ Lagerwaard","year":"2012","unstructured":"Lagerwaard FJ, Verstegen NE, Haasbeek CJA, et al. Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer. Int J Radiation Oncology*Biology*Physics. 2012;83(1):348\u201353.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"5","key":"2571_CR27","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jtho.2022.01.016","volume":"17","author":"XQ Yu","year":"2022","unstructured":"Yu XQ, Yap ML, Cheng ES, et al. Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort. J Thorac Oncol. 2022;17(5):688\u201399.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2571_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jtho.2018.11.018","volume":"14","author":"V Ernani","year":"2019","unstructured":"Ernani V, Appiah AK, Marr A, et al. Adjuvant Systemic Therapy in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiation Therapy. J Thorac Oncol. 2019;14(3):475\u201381.","journal-title":"J Thorac Oncol"},{"key":"2571_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.radonc.2018.10.017","volume":"132","author":"BH Kann","year":"2019","unstructured":"Kann BH, Miccio JA, Stahl JM, et al. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiother Oncol. 2019;132:188\u201396.","journal-title":"Radiother Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02571-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T10:26:34Z","timestamp":1734517594000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02571-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02571-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Ethics Committee of Zhongshan Hospital (B2024-103R), and the requirement of informed consent was waived by the Institutional Review Board since this was a retrospective analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"177"}}